|
PGM2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.44440032051807E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.53589996276793E-09 |
| Normal-vs-Stage2 |
6.80679956843733E-10 |
| Normal-vs-Stage3 |
4.0633996167827E-10 |
| Normal-vs-Stage4 |
1.81329995463386E-09 |
| Stage1-vs-Stage2 |
3.313000E-01 |
| Stage1-vs-Stage3 |
3.005200E-01 |
| Stage1-vs-Stage4 |
3.052200E-01 |
| Stage2-vs-Stage3 |
8.706600E-01 |
| Stage2-vs-Stage4 |
9.655400E-01 |
| Stage3-vs-Stage4 |
8.382600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.03800009990607E-10 |
| Normal-vs-AfricanAmerican |
3.77160000009091E-07 |
| Normal-vs-Asian |
5.75149999848534E-08 |
| Caucasian-vs-AfricanAmerican |
6.512600E-01 |
| Caucasian-vs-Asian |
7.041000E-01 |
| AfricanAmerican-vs-Asian |
4.876000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.26839982961258E-10 |
| Normal-vs-Female |
7.79289965890939E-10 |
| Male-vs-Female |
2.419200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.98910004817799E-09 |
| Normal-vs-Age(41-60Yrs) |
1.06750053241456E-10 |
| Normal-vs-Age(61-80Yrs) |
1.90120030829632E-10 |
| Normal-vs-Age(81-100Yrs) |
2.260400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.733700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.345610E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.095000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.739600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.261800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.240200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.599000E-01 |
| Classical-VS-Follicular |
1.300000E-01 |
| Classical-VS-Other |
2.699200E-01 |
| Classical-VS-Normal |
6.05159999889082E-09 |
| Tall-VS-Follicular |
9.530600E-01 |
| Tall-VS-Other |
5.201000E-01 |
| Tall-VS-Normal |
2.3231000012558E-08 |
| Follicular-VS-Other |
5.494000E-01 |
| Follicular-VS-Normal |
5.84590043040123E-10 |
| Other-VS-Normal |
1.498910E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.85479467527261E-11 |
| Normal-vs-N1 |
3.77730069445192E-11 |
| N0-vs-N1 |
1.404950E-01 |
|
|
